<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092456</url>
  </required_header>
  <id_info>
    <org_study_id>V260-009</org_study_id>
    <secondary_id>2004_078</secondary_id>
    <nct_id>NCT00092456</nct_id>
  </id_info>
  <brief_title>Consistency Lots Vaccine Study (V260-009)</brief_title>
  <official_title>Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study was designed to evaluate consistency in the antibody response to three
      manufactured lots of an investigational Rotavirus Vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]</measure>
    <time_frame>42 days following the 3rd vaccination</time_frame>
    <description>Antibody response to 3 manufactured lots of RotaTeq™ and placebo groups, based on the SNA PostDose 3 geometric mean titers (GMTs) (expressed in dilution units) against rotavirus serotypes G1, G2, G3, G4 and P1A[8]</description>
  </primary_outcome>
  <other_outcome>
    <measure>Geometric Mean Antibody Titer(s) (GMT) to Serum Anti-rotavirus Immunoglobulin A (IgA).</measure>
    <time_frame>42 days following the 3rd vaccination</time_frame>
    <description>Post Dose 3 serum samples were assayed for serum anti-rotavirus IgA</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Clinical Adverse Experiences (CAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>Subjects in this study were followed for all CAEs, including intussusception. A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Serious Clinical Adverse Experiences (SCAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>Subjects were followed for all SCAEs. SCAEs are any CAEs occurring at any dose that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Vaccine-Related Clinical AEs (CAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator, who is a qualified physician, as being related to the vaccine according to his/her best clinical judgment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Serious Vaccine-Related Clinical AEs (CAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Discontinued Due to Clinical Adverse Experiences</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Discontinued Due to Vaccine-Related Clinical Adverse Experiences (CAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator who is a qualified physician as being related to the vaccine according to his/her best clinical judgment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Discontinued Due to Serious Clinical Adverse Experiences (SCAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>SCAEs are any CAEs that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects Discontinued Due to Serious Vaccine-related Clinical Adverse Experiences (CAEs)</measure>
    <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
    <description>Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">793</enrollment>
  <condition>Rotavirus Infections</condition>
  <arm_group>
    <arm_group_label>RotaTeq™ Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>~8.81 X 10^7 IU/Dose of RotaTeq™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RotaTeq™ Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>~8.01 X 10^7 IU/Dose of RotaTeq™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RotaTeq™ Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>~6.91 X 10^7 IU/Dose of RotaTeq™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rotavirus vaccine, live, oral, pentavalent</intervention_name>
    <description>Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination</description>
    <arm_group_label>RotaTeq™ Lot 1</arm_group_label>
    <arm_group_label>RotaTeq™ Lot 2</arm_group_label>
    <arm_group_label>RotaTeq™ Lot 3</arm_group_label>
    <other_name>V260</other_name>
    <other_name>RotaTeq™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10
weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants

        Exclusion Criteria:

          -  History of abdominal disorders from a birth defect, intussusception, or abdominal
             surgery

          -  Known or suspected problems with the immune system

          -  Fever at time of immunization

          -  Prior administration of a rotavirus vaccine

          -  History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2004</study_first_posted>
  <results_first_submitted>June 19, 2009</results_first_submitted>
  <results_first_submitted_qc>March 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2011</results_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 10 sites in the United States from 09-May-2003 (first patient in) to 02-Jul-2004
(last dose given).
Last subject completed follow-up: 13-Aug-2004.
All data corrections applied (Frozen File) date: 30-Sep-2004</recruitment_details>
      <pre_assignment_details>Subjects with prior rotavirus disease, chronic diarrhea, and fever at time of immunization were excluded
from the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RotaTeq™ Lot 1</title>
          <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="P2">
          <title>RotaTeq™ Lot 2</title>
          <description>Three oral doses (~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="P3">
          <title>RotaTeq™ Lot 3</title>
          <description>Three oral doses (~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226">Subject assigned to ~8.81 X 10^7 IU/Dose of RotaTeq™ - Lot 1</participants>
                <participants group_id="P2" count="225">Subject assigned to ~8.01 X 10^7 IU/Dose of RotaTeq™ - Lot 2</participants>
                <participants group_id="P3" count="229">Subject assigned to ~6.91 X 10^7 IU/Dose of RotaTeq™ - Lot 3</participants>
                <participants group_id="P4" count="113">Subjects assigned to Placebo-matching RotaTeq™</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="229"/>
                <participants group_id="P4" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="210"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 3</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="210"/>
                <participants group_id="P3" count="200"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="201">Subjects who received 3 scheduled vaccinations; with up to 42 days safety follow-up after each dose</participants>
                <participants group_id="P2" count="208">Subjects who received 3 scheduled vaccinations; with up to 42 days safety follow-up after each dose</participants>
                <participants group_id="P3" count="200">Subjects who received 3 scheduled vaccinations; with up to 42 days safety follow-up after each dose</participants>
                <participants group_id="P4" count="97">Subjects who received 3 scheduled vaccinations; with up to 42 days safety follow-up after each dose</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RotaTeq™ Lot 1</title>
          <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="B2">
          <title>RotaTeq™ Lot 2</title>
          <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="B3">
          <title>RotaTeq™ Lot 3</title>
          <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="229"/>
            <count group_id="B4" value="113"/>
            <count group_id="B5" value="793"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 to 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="228"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]</title>
        <description>Antibody response to 3 manufactured lots of RotaTeq™ and placebo groups, based on the SNA PostDose 3 geometric mean titers (GMTs) (expressed in dilution units) against rotavirus serotypes G1, G2, G3, G4 and P1A[8]</description>
        <time_frame>42 days following the 3rd vaccination</time_frame>
        <population>Per Protocol Population; excluding protocol violators and subjects with invalid data based on laboratory determinations.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]</title>
          <description>Antibody response to 3 manufactured lots of RotaTeq™ and placebo groups, based on the SNA PostDose 3 geometric mean titers (GMTs) (expressed in dilution units) against rotavirus serotypes G1, G2, G3, G4 and P1A[8]</description>
          <population>Per Protocol Population; excluding protocol violators and subjects with invalid data based on laboratory determinations.</population>
          <units>dilution units</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G1 SNA (dilution units)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.9" lower_limit="135.7" upper_limit="207.7"/>
                    <measurement group_id="O2" value="193.2" lower_limit="157.6" upper_limit="236.8"/>
                    <measurement group_id="O3" value="171.0" lower_limit="140.6" upper_limit="208.1"/>
                    <measurement group_id="O4" value="9.3" lower_limit="7.2" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2 SNA (dilution units)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="17.3" upper_limit="24.7"/>
                    <measurement group_id="O2" value="22.6" lower_limit="19.1" upper_limit="26.8"/>
                    <measurement group_id="O3" value="17.8" lower_limit="15.1" upper_limit="20.9"/>
                    <measurement group_id="O4" value="5.9" lower_limit="5.3" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3 SNA (dilution units)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="15.2" upper_limit="21.2"/>
                    <measurement group_id="O2" value="18.5" lower_limit="15.7" upper_limit="21.9"/>
                    <measurement group_id="O3" value="14.6" lower_limit="12.4" upper_limit="17.2"/>
                    <measurement group_id="O4" value="9.6" lower_limit="7.4" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G4 SNA (dilution units)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="57.0" upper_limit="76.4"/>
                    <measurement group_id="O2" value="74.3" lower_limit="64.4" upper_limit="85.7"/>
                    <measurement group_id="O3" value="65.7" lower_limit="55.6" upper_limit="77.5"/>
                    <measurement group_id="O4" value="7.8" lower_limit="6.5" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P1A[8] SNA (dilution units)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="60.0" upper_limit="84.2"/>
                    <measurement group_id="O2" value="72.3" lower_limit="61.4" upper_limit="85.3"/>
                    <measurement group_id="O3" value="65.6" lower_limit="55.0" upper_limit="78.2"/>
                    <measurement group_id="O4" value="10.2" lower_limit="7.6" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A pairwise comparison of lots was made for each serotype, for each pair of lots.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If equivalence was established in all 3 pairwise comparisons for a given serotype, the 3 lots were considered consistent for that serotype. Each comparison consisted of 2 one-sided tests of equivalence with α=0.05. Statistical significance for the 2 one-sided equivalence tests for each pair of lots was established if the p-values for the hypothesis tests were each less than 0.05. This corresponds to the 2-sided 90% CI for the fold difference in the 2 lots being contained entirely within (0.5,2).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The reported p-value is for all 5 serotypes, no multiplicity adjustment made, and Type I error rate controlled at the 0.05 level. P&lt;0.05 implies that the difference is statistically significantly less than the prespecified difference of 2 fold.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A pairwise comparison of lots was made for each serotype, for each pair of lots.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If equivalence was established in all 3 pairwise comparisons for a given serotype, the 3 lots were considered consistent for that serotype. Each comparison consisted of 2 one-sided tests of equivalence with α=0.05. Statistical significance for the 2 one-sided equivalence tests for each pair of lots was established if the p-values for the hypothesis tests were each less than 0.05. This corresponds to the 2-sided 90% CI for the fold difference in the 2 lots being contained entirely within (0.5,2)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The reported p-value is for all 5 serotypes, no multiplicity adjustment made, and Type I error rate controlled at the 0.05 level. P&lt;0.05 implies that the difference is statistically significantly less than the prespecified difference of 2 fold.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A pairwise comparison of lots was made for each serotype, for each pair of lots.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If equivalence was established in all 3 pairwise comparisons for a given serotype, the 3 lots were considered consistent for that serotype. Each comparison consisted of 2 one-sided tests of equivalence with α=0.05. Statistical significance for the 2 one-sided equivalence tests for each pair of lots was established if the p-values for the hypothesis tests were each less than 0.05. This corresponds to the 2-sided 90% CI for the fold difference in the 2 lots being contained entirely within (0.5,2).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The reported p-value is for all 5 serotypes, no multiplicity adjustment made, and Type I error rate controlled at the 0.05 level. P&lt;0.05 implies that the difference is statistically significantly less than the prespecified difference of 2 fold.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Antibody Titer(s) (GMT) to Serum Anti-rotavirus Immunoglobulin A (IgA).</title>
        <description>Post Dose 3 serum samples were assayed for serum anti-rotavirus IgA</description>
        <time_frame>42 days following the 3rd vaccination</time_frame>
        <population>Per Protocol Population; excluding protocol violators and subjects with invalid data based on laboratory determinations.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titer(s) (GMT) to Serum Anti-rotavirus Immunoglobulin A (IgA).</title>
          <description>Post Dose 3 serum samples were assayed for serum anti-rotavirus IgA</description>
          <population>Per Protocol Population; excluding protocol violators and subjects with invalid data based on laboratory determinations.</population>
          <units>units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.7" lower_limit="241.0" upper_limit="355.5"/>
                    <measurement group_id="O2" value="272.5" lower_limit="227.9" upper_limit="325.7"/>
                    <measurement group_id="O3" value="266.2" lower_limit="220.1" upper_limit="321.8"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.2" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Clinical Adverse Experiences (CAEs)</title>
        <description>Subjects in this study were followed for all CAEs, including intussusception. A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>Safety Population: All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Adverse Experiences (CAEs)</title>
          <description>Subjects in this study were followed for all CAEs, including intussusception. A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>Safety Population: All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="212"/>
                    <measurement group_id="O4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Serious Clinical Adverse Experiences (SCAEs)</title>
        <description>Subjects were followed for all SCAEs. SCAEs are any CAEs occurring at any dose that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Clinical Adverse Experiences (SCAEs)</title>
          <description>Subjects were followed for all SCAEs. SCAEs are any CAEs occurring at any dose that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="220"/>
                    <measurement group_id="O3" value="227"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Vaccine-Related Clinical AEs (CAEs)</title>
        <description>CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator, who is a qualified physician, as being related to the vaccine according to his/her best clinical judgment.</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine-Related Clinical AEs (CAEs)</title>
          <description>CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator, who is a qualified physician, as being related to the vaccine according to his/her best clinical judgment.</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="165"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Serious Vaccine-Related Clinical AEs (CAEs)</title>
        <description>Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Vaccine-Related Clinical AEs (CAEs)</title>
          <description>Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With serious vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="229"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Discontinued Due to Clinical Adverse Experiences</title>
        <description>A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discontinued Due to Clinical Adverse Experiences</title>
          <description>A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discontinued due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="228"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Discontinued Due to Vaccine-Related Clinical Adverse Experiences (CAEs)</title>
        <description>CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator who is a qualified physician as being related to the vaccine according to his/her best clinical judgment.</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discontinued Due to Vaccine-Related Clinical Adverse Experiences (CAEs)</title>
          <description>CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator who is a qualified physician as being related to the vaccine according to his/her best clinical judgment.</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discontinued due to vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="229"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Discontinued Due to Serious Clinical Adverse Experiences (SCAEs)</title>
        <description>SCAEs are any CAEs that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discontinued Due to Serious Clinical Adverse Experiences (SCAEs)</title>
          <description>SCAEs are any CAEs that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discontinued due to serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="228"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Discontinued Due to Serious Vaccine-related Clinical Adverse Experiences (CAEs)</title>
        <description>Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
        <time_frame>Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first</time_frame>
        <population>All subjects who were vaccinated and followed up</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Lot 1</title>
            <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ Lot 2</title>
            <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ Lot 3</title>
            <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discontinued Due to Serious Vaccine-related Clinical Adverse Experiences (CAEs)</title>
          <description>Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.</description>
          <population>All subjects who were vaccinated and followed up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to serious vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOTdiscontinued dueto serious vaccine-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="229"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients in this study were followed for all adverse experiences, for up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first.</time_frame>
      <desc>The number of patients listed in the Adverse Event tables (226 – Lot 1, 224 – Lot 2, 229 – Lot 3, and 112 – Placebo) is the number of patients who received study treatment.
Although a patient may have had two or more clinical adverse experiences the patient is counted only once in a category. The same patient may appear in different categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>RotaTeq™ Lot 1</title>
          <description>Three oral doses (~8.81 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="E2">
          <title>RotaTeq™ Lot 2</title>
          <description>Three oral doses ( ~8.01 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="E3">
          <title>RotaTeq™ Lot 3</title>
          <description>Three oral doses ( ~6.91 X 10^7 IU/Dose) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="211" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Regurgitation of food</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

